Perimeter Medical Imaging AI Reports Record Q1 2025 Revenue, Advances AI-Enabled Cancer Detection Technology

Record-Breaking Q1 2025 Performance

Perimeter Medical Imaging AI, Inc. (OTC:PYNKF) has reported exceptional financial results for the first quarter of 2025, marking a significant milestone in the company's growth trajectory. The medical technology firm, specializing in AI-enhanced imaging for cancer detection, announced a staggering 460% year-over-year increase in revenue, reaching $550,269 for Q1 2025 1

1

Perimeter S-Series OCT Gains Traction

The company's FDA-cleared Perimeter S-Series OCT device has shown remarkable market penetration:

• Case volumes increased by 160% year-over-year and 15% sequentially
• April 2025 saw record patient cases supported and highest-ever consumables shipped
• 88% of eligible devices covered by paid ESP warranty programs
• 2025 billings surpassed $1 million by April 1

  1

Perimeter has also expanded its geographical footprint, with first-time deployments in New Mexico, Tennessee, and Arizona healthcare systems.

Advancing AI-Enabled Technology: Perimeter B-Series

Perimeter is making significant strides in developing its next-generation Perimeter B-Series device, which integrates proprietary AI technology with OCT imaging:

• In March 2025, the company submitted a Premarket Approval (PMA) application to the FDA for use during breast-conserving surgeries
• Detailed results from the pivotal trial were presented at the 26th Annual Meeting of the American Society of Breast Surgeons (ASBrS)
• The trial met its primary endpoint, demonstrating a statistically significant reduction in patients with residual cancer during surgery (p-value = 0.0024) 1

  1

Related Stories

Perimeter Medical Imaging AI Announces C$13.5M Private Placement for Cancer Detection Technology

Medical Technology Companies Report Q2 2024 Earnings: Growth, Challenges, and Future Prospects

QT Imaging and Kopin Corporation Report Q2 2024 Financial Results

Q2 2024 Financial Results: A Mixed Bag for Tech and Healthcare Companies

Financial Highlights and Corporate Updates

• Q1 2025 operating expenses remained stable at approximately $4.7 million
• Net loss for Q1 2025 was approximately $4.7 million, or $0.07 per common share
• Cash used in operating activities increased by 6% to approximately $3.7 million
• As of March 31, 2025, the company held approximately $2.7 million in cash 1

  1

Perimeter's common shares began trading on the OTCQX® Best Market under the symbol "PYNKF" on February 27, 2025, while maintaining its listing on the TSX Venture Exchange under "PINK" 1

1

Future Outlook and Ongoing Initiatives

CEO Adrian Mendes expressed optimism about the company's trajectory, stating, "This has been a pivotal start of the year for Perimeter, marked by record revenue from sales of our current S-Series system, the presentation of positive pivotal trial results for our next-generation AI-enabled B-Series product at ASBrS, and of course, the filing of the FDA PMA application for the upcoming B-Series" 2

2

The company plans to submit detailed pivotal trial results for publication in peer-reviewed journals, further solidifying its position in the medical imaging and AI sector 1

1